Tivorbex 2015 report
Tivorbex 2015 U.S. PROMOTIONAL AUDIT REPORT
Published July 2016 • 31 Pages
The 5 Key Questions Addressed by this Report:
- How many physicians were reached by Tivorbex through personal promotion in 2015 and how does this compare to its peer set in the Pain – NSAIDS market?
- What promotional mix was leveraged (e.g., sales rep detailing, physician education, and paid speaking) and what was the median spend on each type of activity?
- How does Iroko’s depth of coverage vary within key specialties (e.g., Family Medicine, Podiatry, Rheumatology, Internal Medicine, Orthopedic Surgery, Physical Medicine and Rehabilitation, and Pain Medicine) and how does this compare to its peers and the overall set of rep-accessible physicians?
- How often are physicians receiving paid meals for Tivorbex throughout the year (e.g., monthly, quarterly, annually)?
- Who were the most detailed prescribers and top paid speakers/consultants for Tivorbex in 2015?
Data Sources and Methodology:
- MDDetails leverages company-reported financial transaction data disclosed through CMS Open Payments. This data set captures all transfers of value (e.g., speaking fees, consulting fees, travel, education, and meals) made on behalf of a drug or device manufacturer to a physician. Currently, 30 months of longitudinal data is available – covering payments to more than 800,000 U.S. healthcare professionals.
- Over 400 paid interactions across 200 physicians made on behalf of Tivorbex were carefully examined to support our analysis. In addition, interaction data from 9 peer products (e.g. Caldolor, Duexis, Flector Patch, Ofirmev, Pennsaid, Sprix, Voltaren Gel, Zipsor, and Zorvolex) was leveraged to provide benchmarking and market insights.